MedPal AI (AIM:MPAL) UK regulator approves first oral GLP-1 weight-loss pill, opening private market opportunity MedPal says it is positioned to capture
Oral semaglutide removes the need for self-injection and is already showing signs of expanding the treatable population in the US.
MedPal AI, which operates the private weight-management clinic New Health, has welcomed UK regulatory approval of the first oral version of a GLP-1 weight-loss drug, saying the development broadens its addressable market and coincides with New Health's national launch.
The Medicines and Healthcare products Regulatory Agency has granted marketing authorisation for oral semaglutide tablets for weight loss, offering patients an alternative to the injectable versions of GLP-1 drugs that have dominated the obesity treatment market.
GLP-1 receptor agonists work by mimicking a gut hormone that regulates appetite and blood sugar, suppressing hunger and slowing digestion. Until now, all approved weight-loss versions in the UK required patients to inject themselves, typically once a week.
The tablet is not currently available on the NHS and remains subject to evaluation by the National Institute for Health and Care Excellence, meaning private clinics are currently the only route to access in the UK.
In the US, where oral semaglutide is already available, Novo Nordisk reported that prescriptions exceeded three million in just over five months, with more than 80% going to patients new to GLP-1 therapy, suggesting the pill format is drawing in people who had previously avoided injectable treatments.
MedPal said its model, which combines artificial intelligence-supported triage, clinician-led prescribing and robotic dispensing, positions New Health to meet anticipated private-market demand.
The company said it will provide a further update on its commercial plans in due course.
